Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Cantargia receives regulatory approval to start CESTAFOUR clinical study with nadunolimab in combination with chemotherapy

Cantargia AB today announced approval to start the phase I/II clinical study CESTAFOUR by the regulatory authority and ethics committee in France. This study broadens the clinical development for nadunolimab (CAN04) to include biliary tract cancer (BTC), colorectal cancer (CRC) and late-stage non-small lung cancer (NSCLC) and will evaluate CAN04 in combination with standard of care chemotherapy. The study will be conducted at approximately 20 clinical centers in Europe and will include up to a total of 165 patients. The first patient is estimated to be enrolled in September/October 2021.

New date for publication of Crunchfish’s interim report for the third quarter 2021

Following the announcement of the rights issue of shares and warrants in Crunchfish AB, the Board of Directors of Crunchfish has decided to postpone the disclosure of the interim report for the third quarter 2021. New publication date is November 30, 2021.Crunchfish has, subject to approval by the Extraordinary General Meeting on September 16, 2021, resolved to carry out a rights issue of shares and warrants, with a subscription period between October 11-25, 2021. Hence, the Board of Directors has decided to postpone the disclosure of the interim report for the third quarter 2021 to

Cantargia completes patient recruitment to the phase IIa pancreatic cancer extension cohort in the CANFOUR study

Cantargia AB today announced that all planned 40 patients with advanced pancreatic cancer (PDAC) have started therapy in the phase IIa extension cohort in the CANFOUR study. Preliminary data from these patients confirm a good safety profile of nadunolimab (CAN04) combined with gemcitabine/nab-paclitaxel. Presentation of safety and efficacy data for the extension cohort is planned for the first half of 2022. Adding this group to the primary group previously analyzed, more than 70 patients with PDAC have now received CAN04 combined with chemotherapy. Preparations are ongoing for a randomized

Sivers Semiconductors recruits new CFO

Sivers Semiconductors AB today announced that the company has recruited Håkan Rippe as new Chief Financial Officer (CFO) from September 20.Håkan Rippe's career spans 27 years in both private equity-owned and listed technology companies. He has been part of several growth journeys and handled a significant number of acquisitions and capital market transactions. Håkan Rippe has previously held the role of CFO at Enea and Clavister as well as senior positions at IBM and Telelogic, among others. “After moving to Nasdaq Stockholm's main list, we are now entering the next phase of our growth

Thailand Reopening continues

  Thailand is set to reopen more popular tourist destinations, Bangkok Chiang Mai, Hua Hin and Pattaya from 1 October. The reopening scheme starts with Phuket Sandbox from 1 July and continues with the Samui Plus from 15 July, Phuket 7+7 Extension from 15 August. It allows fully vaccinated tourists to travel to Thailand without the need to quarantine. The Royal Thai Government has announced plans to reopen Bangkok, Chiang Mai, Chon Buri, Phetchaburi, and Prachuap Khiri Khan from 1 October as part of the second phase of the country’s reopening scheme. From mid-October,

Meetings 2.0 – new meeting practices through piloting

Meetings: A waste of time, or an opportunity to share and refine information while strengthening a sense of community? This catch 22 has led employees to question the logic of meetings, which now consume most of the workday.The global transition from office to remote work has significantly increased the number of online meetings. For Kiiltonians, this new way of life has challenged the old ways of time management, especially when scheduling and attending back-to-back digital meetings without interrupting the natural flow of everyday work. Aware of this growing pain point, Kiilto wanted to

MEPs underline support for moving away from industrial animal farming, increase in plant-based protein and tax on climate-damaging foods

Despite farming lobby resistance, the Farm to Fork report makes valuable policy demands to advance animal welfare and tackling climate change, says Humane Society International/EuropeBrussels (10 Sept. 2021) – MEPs have backed the revision of EU animal welfare legislation, an accelerated transition away from intensive animal agriculture, greater support for plant-based proteins and zero tax for climate-friendly foods with higher tax on climate-damaging foods like meat. The European Parliament’s Committees on Environment, Public Health and Food Safety and on Agriculture and Rural Development

Press release from the Annual General Meeting of Clas Ohlson AB (publ) 10 September 2021

On Friday, 10 September 2021, Clas Ohlson AB held its Annual General Meeting (AGM) for the 2020/21 financial year through advance voting (postal voting) in accordance with the Swedish Act on Temporary Exemptions to Facilitate the Execution of General Meetings in Companies and Associations (2020:198). Accordingly, shareholders participated in the Meeting by voting in advance on the motions to the Meeting and submitting questions, where the main resolutions below were made.For more detailed information on the content of the resolutions, please refer to the press release published on 4 August

Composition of Terveystalo Pcl’s shareholders’ nomination board

Terveystalo Plc Stock Exchange Release 10 September 2021 at 12:40 EEST The Shareholders' Nomination Board of Terveystalo Plc comprises the representatives of the four largest shareholders of the company as at 1 September 2021 and, in addition, the Chairman of the Board of Directors. The duties of the Nomination Board include, for example, the search, preparation and presentation of member candidates for the Board of Directors as well as matters concerning the remuneration of the Board of Directors. The Nomination Board shall elect a Chairman from amongst its members. In accordance

Tourist Flows Continues Despite The New ECDC Map Update

Despite the fact that Croatia has been added to the list of “red” countries / regions on the map of the European Center for Disease Prevention and Control (ECDC), thanks to the standardization of travel processes within the EU, tourist flows still continues.The same or similar rules for travel apply for most countries, in accordance with thei respective epidemiological situations. Regardless of Croatia being in the "red", tourists that return to their home countries are currently not required to self-isolate, but are required to present a negative PCR or rapid antigen test, unless they have

New Business Update - Ayima Group AB

Further to our previous update of 26 August, Ayima is pleased to announce it has this week signed further new customer agreements totalling aproximately 1.6 MSEK. the new agreements include expansion to new SEO and Content services for a FTSE100 e-commerce company based in London.  the new agreements bring the total of new business signed in 2021 to approxiamtely 53.6 MSEK and is a strong indicator of Ayima's return to rapid growth

CS MEDICA’s clinical trial Phase III results from the intermediate report on NGA-01 (CANNASEN®CBD Arthritis Gel) against placebo

Today, September 10[th], 2021, CS MEDICA A/S’s (”CS MEDICA” or the ”Company”) can announce that the CANNASEN®CBD Arthritis Gel (NGA-01) has, after conducting the final efficacy analysis in the ongoing Phase III trial, met all the trial’s primary efficacy endpoints. Analysis of the data indicates that CANNASEN®CBD Arthritis Gel (NGA-01) has an efficacy rate of 89 percent in reduction of pain in joints of participants with Osteoarthritis with joint pain in any of the joints; knee, hip, ankle, elbow, and shoulder. The data of the trial shows that the CANNASEN®CBD Arthritis Gel (NGA-01) was well

BioGaia Pharma secures approval for two clinical trials for its pharmaceutical candidates

BioGaia Pharma has received formal approval from relevant authorities to proceed with both of its planned clinical trials. The trials are the next phase in the development of BioGaia Pharma’s two pharmaceutical product candidates. The biologics both contain a single strain live microbial as API. Recruitment will start during late 2021.The first program BGP014 is for Ulcerative Colitis (UC). UC is a debilitating condition characterised by chronic inflammation in the intestinal tract affecting roughly 2,5 million patients in Europe and the US alone. There is no cure for UC and patients need

Vitec acquires the software company Vabi in the Netherlands

Vitec Software Group AB (publ) is strengthening its position in Vertical Market Software on September 10 by acquiring all shares in the Dutch software company Vabi Holding B.V. The company reported sales of EUR 6.8 million with an EBITDA result of EUR 4.25 million for the 2020 financial year.Vabi develops and provides software that contributes to sustainable and efficient energy management for the real estate industry. The products have several functions such as decision support systems, user-friendly 3D simulations and energy certification for reduced climate impact. Payment will be in

BioStock: Lipum is at the final step before clinical phase

Late last week, Lipum announced that the toxicology and safety studies with the drug candidate SOL-116 are proceeding according to plan. The company has started the final study before a Clinical Trial Application can be filed and it looks like the first clinical trial with SOL-116 is on track to begin next year. BioStock contacted Anneli Hällgren, project manager for the toxicology and safety program, to learn more about the progress in the preclinical work.Read the full interview at biostock.se: https://www.biostock.se/en/2021/09/lipum-is-at-the-final-step-before-clinical-phase/ 

Notification of transactions by persons discharging managerial responsibilities and persons closely associated with them in Penneo A/S

Company Announcement No. 20-2021Copenhagen, 10 September 2021 In accordance with the Market Abuse Regulation, Penneo must notify Finanstilsynet and publicly disclose transactions made by persons discharging managerial responsibilities and persons closely associated with them on trading of Penneo shares. Penneo hereby notify and submit the following transaction of shares in Penneo: Name: Flora IT ApSTitle: Legal person closely associated with Jan Flora (Chief Technology Officer of Penneo)Reason for

Detection Technology’s financial calendar for 2022

Detection Technology Plc company announcement 10 September 2021 at 10:00 (EEST) Detection Technology’s financial calendar for 2022 Detection Technology Plc will disclose the following financial releases in 2022: · Financial statements review 2021: 2 February 2022 · Business review January–March 2022: 27 April 2022 · Half-yearly report January–June 2022: 3 August 2022 · Business review January–September 2022: 26 October 2022 The financial statements and annual review for 2021 will be published latest on 9 March 2022 on the company’s website. The Annual General Meeting

Next Bridge Solution from LNG to Ammonia: Development of a Concept Design for “Ammonia-fuel Ready LNG-Fueled Vessel” Is Launched

Nippon Yusen Kabushiki Kaisha (hereinafter, NYK), MTI Co., Ltd. (hereinafter, MTI), and Elomatic, a Finnish consulting and engineering firm, launched the development of a concept design for “Ammonia-fuel Ready LNG-Fueled Vessel” (ARLFV), which covers the transition to future marine fuel.1. Background Currently, NYK and MTI (hereinafter, the NYK Group) promotes upgrading its fleet via the use of LNG, a low-carbon marine fuel, to achieve NYK’s mid- and long-term environmental targets*. The LNG-fueled vessel is set as a bridge solution to future marine fuel. The NYK Group also participates

BioStock: Positive outcome for Alligator Bioscience’s joint study with Scandion Oncology

A little more than a year has passed since Alligator Bioscience and Scandion Oncology announced the start of a joint project exploring the anti-tumour effect in chemotherapy-resistant tumours using mitazalimab and SCO-101 together with chemotherapy Folfirinox. The companies have now achieved a positive outcome of their preclinical study and concluded their collaboration.Read the article about Alligator Bioscience at biostock.se: https://www.biostock.se/en/2021/09/positive-outcome-for-alligator-biosciences-joint-study-with-scandion-oncology/ This is a press release from BioStock -

Last day of trading in warrants of series TO5 is September 16, 2021

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm, Denmark, September 10, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion") announces that Thursday, September 16, 2021 is the last day of trading in warrants of series TO5. The exercise period for warrants of series TO5 runs to

Peter L Nilsson to join BoMill as business advisor

Peter L Nilsson adds substantial expertise and knowhow from international business and the global food industry. He will be a valuable addition to BoMill’s ambition to reach out globally with the company’s revolutionary solution. BoMill’s unique sorting technology enables optimum grain usage, based on a kernel-by-kernel assessment of its inner properties.Peter L Nilsson has an extensive career from international business and executive management positions in companies such as Tetra Pak, Coca-Cola, Hilti, and Findus. He was appointed CEO of Ecolean Group in 2007, a position he still holds,

Atlas Copco’s SvP Chief Communications Officer Gisela Lindstrand will leave the Group

Nacka, Sweden, September 10, 2021: Gisela Lindstrand, Senior Vice President Chief Communications Officer, will leave the Atlas Copco Group on September 30, 2021.Cecilia Sandberg, Senior Vice President Chief Human Resources Officer, has been appointed acting Senior Vice President Chief Communications Officer. Gisela Lindstrand joined the Group in 2018 as Senior Vice President Chief Communications Officer and has been a member of Group Management. The recruitment for her replacement will start immediately.

Change in Board of Directors

ICA-handlarnas Förbund, which is the majority owner of ICA Gruppen, announced on 8 September 2021 that Fredrik Hägglund has left his position as CEO of ICA-handlarnas Förbund. Fredrik Hägglund thereafter announced his departure from ICA Gruppen’s board of directors. A successor will be elected in connection with ICA Gruppen’s next general meeting of shareholders. For more information:Frans Benson, Head of Investor RelationsTelephone number: +46 (0)8 561 500 20

Evolution to acquire DigiWheel

[PR] Evolution today announces that it has entered into an agreement to acquire the business of DigiWheel, developers of a unique HD spinning gaming wheel.The acquisition is an all cash deal with a total up-front consideration of EUR 1 million. In addition, Evolution will pay an earn-out payment, based on DigiWheel’s net income for the third year following closing.  According to Evolution, the deal will further strengthen Evolution’s online gaming portfolio through DigiWheel’s unique and innovative digital technology being blended into Evolution’s online Live Casino games and game shows.

There are no items matching the current filter
There are no more items matching the current filter
Back to top